Comments
Loading...

SAB Biotherapeutics

SABSNASDAQ
Logo brought to you by Benzinga Data

SAB Biotherapeutics (NASDAQ:SABS) Stock Quotes, Forecast and News Summary

SAB Biotherapeutics Stock (NASDAQ: SABS) stock price, news, charts, stock research, profile.

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change
Analyst Trends and Forecast
1
Jun
3
Aug
2
Sep
1
Oct
1
Nov
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.1
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
Open$3.25
Close-
Volume / Avg.4.43K / 71.71K
Day Range$3.11 - $3.25
52 Wk Range2.16 - 9.72
Market Cap$28.66M
P/E Ratio-
Dividend Yield-
ExchangeNASDAQ
RSI
49
Short Interest
0.84%
Days to Cover1

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
SABS
ERNA

FAQ

Q

How do I buy SAB Biotherapeutics (SABS) stock?

A

You can purchase shares of SAB Biotherapeutics (NASDAQ:SABS) through any online brokerage.

View our list of the best stock brokerages

Q

Who are SAB Biotherapeutics (SABS) competitors?

Q

What is the forecast, or price target, for SAB Biotherapeutics (SABS) stock?

A

SAB Biotherapeutics has a consensus price target of $12.40.

Q

What is the current price for SAB Biotherapeutics (SABS)?

A

The stock price for SAB Biotherapeutics (NASDAQ: SABS) is $3.105 last updated November 21, 2024 at 9:45 AM EST.

Q

Does SAB Biotherapeutics (SABS) pay a dividend?

A

There are no upcoming dividends for SAB Biotherapeutics.

Q

When is SAB Biotherapeutics (NASDAQ:SABS) reporting earnings?

A

SAB Biotherapeutics’s Q3 earnings are confirmed for Wednesday, November 6, 2024.

Q

Is SAB Biotherapeutics (SABS) going to split?

A

There is no upcoming split for SAB Biotherapeutics.

Q

What sector and industry does SAB Biotherapeutics (SABS) operate in?

A

SAB Biotherapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch